What is eugenol and what is it used for?

Eugenol is a naturally occurring phenylpropanoid compound found at 45–90% concentration in clove essential oil (Syzygium aromaticum), with additional sources including cinnamon and basil. It is used clinically as a topical dental analgesic in zinc oxide eugenol formulations, and is under preclinical investigation for anti-inflammatory, antimicrobial, antioxidant, and anticancer applications, though systemic supplementation lacks validated human trial support.

Is eugenol safe to take as a supplement?

Eugenol holds FDA GRAS status for food flavoring and is considered non-carcinogenic and non-mutagenic at typical dietary exposure; the WHO/FAO acceptable daily intake is 2.5 mg/kg body weight per day (approximately 175 mg for a 70 kg adult). At higher doses, eugenol exhibits dose-dependent prooxidant and hepatotoxic effects, and undiluted topical application can cause mucosal burns; use during pregnancy is not recommended beyond food amounts due to theoretical uterotonic effects.

What foods are high in eugenol?

Clove buds and their steam-distilled essential oil are the richest dietary source of eugenol, with the compound comprising 45–90% of clove oil and approximately 24.37 mg/g in aromatic clove extracts as measured by GC-MS. Other meaningful dietary sources include cinnamon bark oil (20–50% eugenol), nutmeg, bay leaf, basil, tulsi, and ginger, though these contain substantially lower concentrations and contribute minimal eugenol at typical culinary use levels.

Does eugenol have anticancer properties?

Preclinical in vitro research shows eugenol can induce apoptosis in cancer cell lines and inhibit tumor metastasis pathways through prooxidant ROS generation at high concentrations; it synergizes with the chemotherapeutic drug gemcitabine to reduce pancreatic cancer cell viability to 47% combined versus 84% (eugenol alone at 150 µM) and 51% (gemcitabine alone at 15 µM). However, these findings are entirely from cell culture models—no human clinical trials have investigated eugenol as an anticancer agent, and clinical translation cannot be assumed from current data.

Does eugenol interact with blood thinners or anticoagulant medications?

Eugenol may have mild antiplatelet properties and should be used cautiously with blood thinners like warfarin or aspirin, as it could theoretically potentiate their effects. Limited clinical data exists on significant interactions, but individuals taking anticoagulants should consult a healthcare provider before supplementing with eugenol to assess individual risk factors. Most concerns are theoretical rather than based on documented adverse events at typical dietary levels.

Is eugenol safe during pregnancy and breastfeeding?

Eugenol safety during pregnancy and breastfeeding has not been adequately studied in human clinical trials, and high doses are traditionally avoided during these periods due to potential uterotonic effects. While eugenol from food sources (such as small amounts in cloves) is generally considered safe, concentrated supplements should not be used without explicit medical guidance during pregnancy or lactation. Pregnant and nursing women should consult their healthcare provider before supplementing with eugenol.

How does eugenol's anti-inflammatory mechanism compare to NSAIDs like ibuprofen?

Both eugenol and NSAIDs reduce inflammation by suppressing prostaglandin production, but eugenol inhibits COX-2 expression through phenolic mechanisms while NSAIDs directly block COX-1 and COX-2 enzyme activity. Eugenol achieves up to 98.3% PGE2 reduction in cell studies, though human clinical efficacy data is more limited than for established NSAIDs. Eugenol may offer a gentler alternative with potentially fewer gastrointestinal side effects, but direct comparative clinical trials in humans remain sparse.

Eugenol

Eugenol is a phenylpropanoid that exerts analgesic, anti-inflammatory, and antimicrobial effects primarily by inhibiting inducible COX-2, scavenging reactive oxygen species, and disrupting microbial membrane integrity. In LPS-activated RAW264.7 macrophages, eugenol at 10 µg/mL suppressed prostaglandin E2 production by 98.3%, demonstrating potent in vitro anti-inflammatory efficacy, though equivalent human clinical trial data remain limited.

Category: Compound Evidence: 1/10 Tier: Preliminary

Origin & History

Eugenol is a naturally occurring phenylpropanoid found at highest concentrations (45–90%) in the essential oil of clove (Syzygium aromaticum, syn. Eugenia caryophyllata), a tropical evergreen tree native to the Maluku Islands (Spice Islands) of Indonesia and widely cultivated across Madagascar, Tanzania, Sri Lanka, and India. It is also present in significant amounts in cinnamon bark oil (20–50%), as well as in smaller quantities in nutmeg, basil, bay leaf, ginger, and tulsi. Clove buds, stems, and leaves are harvested and processed via steam distillation or solvent extraction, with the buds yielding the highest eugenol concentration.

Historical & Cultural Context

Clove, the primary eugenol source, has been traded for over 2,000 years, with historical records tracing its use to Han Dynasty China (circa 200 BCE), where courtiers chewed cloves before addressing the emperor to freshen breath—an early recognition of its antimicrobial oral properties. In Ayurvedic medicine, clove (Lavanga) has been employed for millennia as a digestive stimulant, analgesic for toothache, and respiratory remedy, with preparations including decoctions, medicated oils, and powdered formulations incorporated into classical texts such as the Charaka Samhita. Arab traders controlled the clove spice routes through the medieval period, and Portuguese, Dutch, and British colonial powers subsequently competed for monopoly over Maluku Island clove cultivation, reflecting eugenol-rich clove's enormous historical economic and medicinal value. In European traditional medicine and early 19th-century dentistry, oil of cloves became the standard of care for toothache relief, a practice that directly evolved into the zinc oxide eugenol formulations still used in contemporary dental practice.

Health Benefits

- **Anti-Inflammatory Activity**: Eugenol inhibits inducible COX-2 enzyme expression and reduces prostaglandin E2 (PGE2) production by up to 98.3% at 10 µg/mL in macrophage cell models, attenuating the cyclooxygenase-driven inflammatory cascade.
- **Analgesic Properties**: By suppressing PGE2 synthesis and modulating transient receptor potential (TRP) channels, eugenol reduces pain signaling; it has a well-documented topical dental analgesic application used clinically in zinc oxide eugenol formulations.
- **Antimicrobial Efficacy**: Eugenol disrupts bacterial and fungal cell membranes, inhibits biofilm formation, and has demonstrated activity against pathogens including Staphylococcus aureus, Escherichia coli, and Candida albicans, with minimum inhibitory concentrations in the µg/mL range across multiple in vitro studies.
- **Antioxidant Defense**: At physiologically relevant low doses, eugenol scavenges reactive oxygen species (ROS) and chelates metal ions through its phenolic hydroxyl group, contributing to cellular protection against oxidative damage.
- **Anticancer Potential**: Eugenol induces apoptosis, inhibits tumor metastasis pathways, and synergizes with the chemotherapeutic agent gemcitabine—reducing pancreatic cancer cell viability from 84% (eugenol alone at 150 µM) to 47% when combined with gemcitabine at 15 µM in vitro.
- **Neuroprotective Effects**: Preclinical evidence suggests eugenol attenuates neuroinflammation and oxidative stress in neuronal cell models, potentially through NF-κB pathway suppression and mitochondrial stabilization, though human data are absent.
- **Platelet Aggregation Inhibition**: Eugenol and its derivatives interfere with collagen- and PGE2-mediated platelet aggregation pathways, suggesting potential cardiovascular protective effects that require further clinical validation.

How It Works

Eugenol's primary anti-inflammatory mechanism involves transcriptional downregulation of inducible cyclooxygenase-2 (COX-2) and subsequent reduction of prostaglandin E2 biosynthesis, with concurrent modulation of IL-8 secretion in a concentration-dependent biphasic manner—stimulation at 5 µM and inhibition at 500 µM in hepatocyte growth factor-stimulated cells. Its antioxidant activity is mediated through the phenolic hydroxyl group at the C-4 position, which donates hydrogen atoms to neutralize free radicals and chelate pro-oxidant metal ions; paradoxically, at high concentrations, eugenol generates ROS through auto-oxidation, producing cytotoxic prooxidant effects that may contribute to its anticancer activity via mitochondrial-dependent apoptosis pathways. Antimicrobial action involves intercalation into phospholipid bilayers of microbial membranes, increasing permeability, dissipating proton motive force, and inhibiting ATPase activity, with additional inhibition of microbial efflux pumps and biofilm-related gene expression. Eugenol also interacts with transient receptor potential vanilloid (TRPV) channels and inhibits voltage-gated sodium channels, contributing to its local anesthetic and analgesic properties.

Scientific Research

The research base for eugenol is substantial at the preclinical level, comprising numerous in vitro cell culture studies and animal model experiments, but it is critically deficient in rigorously designed human clinical trials with adequate sample sizes, randomization, and reported effect sizes. In vitro studies using murine macrophage lines (RAW264.7), hepatocyte growth factor models, and various cancer cell lines have quantified specific molecular outcomes such as 98.3% PGE2 inhibition at 10 µg/mL and synergistic anticancer effects with gemcitabine, providing mechanistic clarity but limited translational certainty. Animal studies have explored anti-inflammatory, neuroprotective, and antitumor effects across rodent models, yet dose extrapolation to humans is confounded by eugenol's poor aqueous solubility and variable bioavailability. No published randomized controlled trials with defined human cohorts, primary endpoints, or statistical power calculations were identified for systemic supplementation indications; clinical use of eugenol as a dental analgesic (zinc oxide eugenol cements) represents the most established human application, though formal RCT data on systemic supplemental dosing remain absent.

Clinical Summary

Clinical evidence for eugenol is presently confined to its well-established topical dental use (in zinc oxide eugenol formulations) and does not extend to rigorously validated systemic supplementation indications in humans. The preponderance of available data derives from in vitro assays and rodent studies, where outcomes such as PGE2 inhibition (98.3% at 10 µg/mL), synergistic cytotoxicity with gemcitabine, and antimicrobial minimum inhibitory concentrations have been reliably quantified. No published human RCTs with defined sample sizes, control arms, or reported p-values and effect sizes (such as Cohen's d) were identified for anti-inflammatory, analgesic, or anticancer applications via oral or systemic routes. Confidence in translating preclinical findings to clinical recommendations is low, and WHO/FAO-established acceptable daily intake of 2.5 mg/kg body weight serves as the primary safety-guided dosing reference rather than efficacy-driven clinical trial data.

Nutritional Profile

Eugenol is a pure phenylpropanoid compound (molecular formula C10H12O2, molecular weight 164.2 g/mol) and does not contribute meaningful macronutrients, micronutrients, or caloric value in supplemental or dietary quantities. As a secondary plant metabolite, its biological relevance lies in its phytochemical activity rather than nutritional density; clove buds, as the whole food matrix, contain small amounts of dietary fiber, manganese (~30 mg/100g), vitamin K, and vitamin C, but these are matrix-dependent and not attributable to eugenol itself. Eugenol's bioavailability is notably limited by poor aqueous solubility (solubility ~2.5 g/L in water at 25°C), first-pass hepatic metabolism to eugenol glucuronide and sulfate conjugates, and rapid systemic clearance, resulting in low and variable plasma concentrations following oral exposure. Encapsulation technologies (cyclodextrin complexes, lipid nanoparticles, nanoemulsions) are under investigation to enhance bioaccessibility and extend plasma residence time, with early-stage results showing improved in vitro release profiles.

Preparation & Dosage

- **Clove Essential Oil (Topical/Dental)**: 72–90% eugenol content by GC-MS; applied neat or diluted (1–5% in carrier oil) for topical analgesia; clinical dental formulations use zinc oxide eugenol pastes standardized for eugenol release.
- **Clove Bud Powder (Oral Traditional Use)**: Typically 1–3 g dried clove powder per day in traditional Ayurvedic and Unani preparations; eugenol content approximately 15–20% of dry weight.
- **Standardized Clove Extract (Supplement Capsules)**: Extracts standardized to 45–85% eugenol; doses studied in preclinical contexts range from 10–150 µM in vitro; no validated oral human dose established.
- **WHO/FAO Acceptable Daily Intake**: 2.5 mg/kg body weight per day (~175 mg/day for a 70 kg adult); this is a safety ceiling, not an efficacy dose.
- **Nano/Micro-Encapsulated Forms**: Emerging delivery systems using cyclodextrin inclusion complexes or lipid nanoparticles designed to improve aqueous solubility and systemic bioavailability; no standardized commercial dose established.
- **Steam-Distilled Essential Oil (Aromatherapy)**: Diffusion or inhalation of clove oil at concentrations of 1–2% in diffuser blends; systemic absorption via inhalation is minimal and unstudied in formal trials.
- **Timing**: No evidence-based timing guidance exists for systemic supplementation; topical dental applications are used on an as-needed basis.

Synergy & Pairings

Eugenol demonstrates documented in vitro synergy with gemcitabine in pancreatic cancer cell models, where combined treatment at 150 µM eugenol and 15 µM gemcitabine reduced cell viability to 47% compared to 84% and 51% achieved by each agent alone, suggesting additive or synergistic apoptotic pathway engagement. In formulation science, pairing eugenol with cyclodextrin (β-cyclodextrin inclusion complexes) or phospholipid-based nanocarriers markedly improves aqueous solubility and membrane permeability, effectively amplifying bioavailable active fraction without increasing total dose. Traditional Ayurvedic and naturopathic formulations historically combine eugenol-rich clove with piperine-containing black pepper, which may enhance eugenol absorption through CYP enzyme modulation and P-glycoprotein inhibition, a mechanism analogous to piperine's well-characterized bioenhancer role with curcumin, though eugenol-piperine co-administration has not been formally studied in humans.

Safety & Interactions

Eugenol carries FDA GRAS (Generally Recognized as Safe) status for food flavoring applications and has been assessed as non-carcinogenic and non-mutagenic at typical dietary exposure levels; however, dose-dependent toxicity becomes significant at elevated concentrations through prooxidant ROS generation, hepatotoxic potential at supraphysiological doses, and hemolytic activity in concentrated forms. Topically, undiluted clove oil can cause contact dermatitis, oral mucosal irritation, and chemical burns, particularly in pediatric dental applications without appropriate dilution protocols. Known pharmacodynamic interaction exists with gemcitabine (synergistic cytotoxicity in pancreatic cancer cell models), and theoretical interactions with anticoagulant drugs (warfarin, NSAIDs) are plausible given eugenol's platelet aggregation inhibitory properties, though human pharmacokinetic interaction data are not formally documented. Eugenol should be used with caution during pregnancy and lactation—it stimulates uterine contractions at high doses in animal models, suggesting a theoretical abortifacient risk; use beyond food flavoring levels is not recommended in these populations, and individuals with bleeding disorders or on anticoagulant therapy should seek medical guidance before supplementation.